Magrolimab + azacitidine in untreated higher-risk MDS

David Sallman, MD, Moffit Cancer Center, Tampa, FL, describes the mechanism of action of magrolimab, and reports the final results of a Phase Ib study investigating the safety and tolerability of magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes (MDS) (NCT03248479). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.